SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Liesveld Jane)
 

Sökning: WFRF:(Liesveld Jane) > Collection of Perip...

Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors

Hsu, Jack W. (författare)
Univ Florida, Coll Med, Div Hematol & Oncol, Gainesville, FL 32610 USA.
Shaw, Bronwen E. (författare)
Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
Kim, Soyoung (författare)
Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
visa fler...
Logan, Brent R. (författare)
Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
Sees, Jennifer A. (författare)
Ctr Int Blood & Marrow Transplant Res, Natl Marrow Donor Program Be Match, Minneapolis, MN USA.
Confer, Dennis L. (författare)
Ctr Int Blood & Marrow Transplant Res, Natl Marrow Donor Program Be Match, Minneapolis, MN USA.;Natl Marrow Donor Program Be Match, Minneapolis, MN USA.
Pulsipher, Michael A. (författare)
Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, USC Keck Sch Med, Los Angeles, CA 90027 USA.
Shah, Nirali (författare)
NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
Switzer, Galen E. (författare)
Univ Pittsburgh, Med Ctr, Canc Ctr, Pittsburgh, PA USA.
Abidi, Muneer H. (författare)
Spectrum Hlth Hosp Grp, Hematol & Oncol, Grand Rapids, MI USA.
Ahmed, Ibrahim A. (författare)
Childrens Mercy Hosp & Clin, Dept Hematol Oncol & Bone Marrow Transplantat, Kansas City, MO USA.
Anderlini, Paulo N. (författare)
Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
Bredeson, Christopher (författare)
Ottawa Hosp Blood & Marrow Transplant Program, Ottawa, ON, Canada.;Ottawa Hosp Res Inst, Ottawa, ON, Canada.
Chhabra, Saurabh (författare)
Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.
Dandoy, Christopher E. (författare)
Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA.
Angel Diaz, Miguel (författare)
Hosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain.
Farhadfar, Nosha (författare)
Univ Florida, Coll Med, Div Hematol & Oncol, Gainesville, FL 32610 USA.
Ganguly, Siddhartha (författare)
Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.
Gergis, Usama (författare)
New York Presbyterian Hosp, Dept Med Oncol, Hematol Malignancies & Bone Marrow Transplant, Weill Cornell Med Coll, New York, NY USA.
Hale, Gregory A. (författare)
Johns Hopkins All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL USA.
Hematti, Peiman (författare)
Univ Wisconsin Hosp & Clin, Div Hematol Oncol Bone Marrow Transplantat, Dept Med, Madison, WI 53792 USA.
Kamble, Rammurti T. (författare)
Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA.
Kasow, Kimberly A. (författare)
Univ N Carolina, Pediat, Chapel Hill, NC 27515 USA.
Lazarus, Hillard M. (författare)
Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USA.
Liesveld, Jane L. (författare)
Univ Rochester, Med Ctr, Dept Med, Strong Mem Hosp, Rochester, NY 14642 USA.
Murthy, Hemant S. (författare)
Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL 32224 USA.
Olsson, Richard (författare)
Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden
Savani, Bipin N. (författare)
Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.
Schears, Raquel (författare)
Mayo Clin & Mayo Grad Sch Med, Dept Emergency Med, Rochester, MN USA.
Seo, Sachiko (författare)
Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.
Solh, Melhern (författare)
Northside Hosp, Blood & Marrow Transplant & Leukemia Program, Blood & Marrow Transplant Program, Atlanta, GA USA.
Spitzer, Thomas (författare)
Massachusetts Gen Hosp, Cellular Therapy & Transplantat Lab, Boston, MA 02114 USA.
Steinberg, Amir (författare)
Mt Sinai Med Ctr, New York, NY 10029 USA.
Sugrue, Michele (författare)
LifeSouth Community Blood Ctr, Gainesville, FL USA.
Warkentin, Phyllis (författare)
Nebraska Med, Omaha, NE USA.
Wingard, John R. (författare)
Univ Florida, Coll Med, Div Hematol & Oncol, Gainesville, FL 32610 USA.
visa färre...
Univ Florida, Coll Med, Div Hematol & Oncol, Gainesville, FL 32610 USA Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (creator_code:org_t)
Elsevier BV, 2020
2020
Engelska.
Ingår i: Biology of blood and marrow transplantation. - : Elsevier BV. - 1083-8791 .- 1523-6536. ; 26:6, s. 1210-1217
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Peripheral blood stem cells (PBSCs) have been increasingly used for allogeneic hematopoietic cell transplantation instead of bone marrow stem cells. Current National Marrow Donor Program policy recommends 5 days of daily filgrastim, followed by either 1 or 2 days of apheresis for unrelated donors, depending on collection center choice. To date, there are no published studies comparing the differences in donor experience between 1 day and 2 days of apheresis. We examined 22,348 adult unrelated donor collections in 184 centers between 2006 and 2016. Of these 22,348 donors, 20,004 (89.5%) had collection on 1 day, and the other 2344 (9.5%) had collection over 2 days. Information on why donors underwent apheresis in 1 day or 2 days was not available. Donors who underwent apheresis in 1 day were more likely to be male (67% versus 46%; P < .001), younger (age <30 years, 48% versus 36%; P < .001), and have a higher body weight (83.0 kg versus 75.9 kg; P< .001) and body mass index (BMI; >30, 30% versus 22%; P < .001). Successful collection of the requested CD34(+) cell count was achieved on the first day in 82% of 1-day collections and in 16% of 2-day collections. Despite not administering filgrastim the evening after the first day of collection in patients who underwent 2 days of apheresis, the median concentration of CD34' cells/I, in the product was higher on the second day of apheresis compared with the first day (23.8 x 10(6) CD34(+)/L. on day 1 versus 28.7 x 10(6) CD34(+)/L. on day 2; P< .001). Donors who underwent collection in 1 day were less likely to experience citrate toxicity (36% versus 52%; P< .001), hospitalization (1% versus 6%; P< .001), and other side effects related to apheresis (Modified Toxicity Criteria incidence: 20% versus 26%; P < .001). Female sex, older age, collection via central lines, and higher BMI were factors associated with greater likelihood for the development of toxicity, whereas less toxicity was noted in those with higher CD34(+) counts and more blood processed on the first day of collection. We conclude that although unrelated donors can be successfully collected in 1 day or 2 days, 1-day apheresis procedures were associated with less overall toxicity, and thus we recommend single-day collections, especially if the requested number of cells have been collected in 1 day.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Apheresis
Unrelated donor
Donor toxicity

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy